{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Metastatic Colorectal Cancer"],"disease":["Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2693053"],"location":["China"],"study_start_month":["4"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Phase I/II Study of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab as a First-Line Therapy for Patients with Metastatic Colorectal Cancer","description":"Interventions: experimental group:XELOXIRI/bevacizumab\nPrimary outcome(s): DLT;MTD;RP2D;ORR\nStudy Design: Single arm","dates":{"creation":"2020-04-15"},"accession":"2693053","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2000032590"]}}